Known targets — ChEMBL curated mechanism
DRD2DRD3DRD4GNRHRHRH1HTR2AHTR2CSLC6A2SLC6A4SSTR1SSTR2SSTR3SSTR5
The experimentally established mechanism targets of Pamoic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.38 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.71 |
| ▸ | POLB | P06746 | 1/20 | 0.71 |
| ▸ | ME2 | P23368 | 1/20 | 0.56 |
| ▸ | ME1 | P48163 | 1/20 | 0.56 |
| ▸ | ME3 | Q16798 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pamoic Acid SCHEMBL8894325 | 0.98 | GPR35 (0.69) | GPR35POLBME2ME1ME3 | |
| Pamoic Acid SCHEMBL5420259 | 0.97 | GPR35 (0.71) | GPR35POLBME2ME1ME3 | |
| Pamoic Acid SCHEMBL11315960 | 0.97 | GPR35 (0.71) | GPR35POLBME2ME1ME3 | |
| Pamoic Acid SCHEMBL1457853 | 0.97 | GPR35 (0.71) | GPR35POLBME2ME1ME3 | |
| Pamoic Acid SCHEMBL587128 | 0.97 | GPR35 (0.71) | GPR35POLBME2ME1ME3 | |
| Pamoic Acid SCHEMBL517728 | 0.97 | GPR35 (0.71) | GPR35POLBME2ME1ME3 | |
| Pamoic Acid SCHEMBL5012893 | 0.94 | POLB (0.83) | GPR35POLBME2ME1ME3 | |
| Pamoic Acid SCHEMBL5014430 | 0.91 | POLB (0.83) | GPR35POLBME2ME1ME3 | |
| Pamoic Acid SCHEMBL11812243 | 0.84 | GPR35 (0.94) | GPR35POLBME2ME1ME3 | |
| Pamoic Acid SCHEMBL446833 | 0.83 | GPR35 (1.00) | GPR35POLBME2ME1ME3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 549 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688804-A1 | METHODS OF MANUFACTURING PEPTIDE SALTS | Ferring BV (NL) | 2026-02-11 | — | — | EP | claimed |
| US-12516429-B2 | Carbon-supported NiO electrode | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2026-01-06 | — | — | US | claimed |
| US-20250347010-A1 | ELECTROCHEMICAL CELL WITH NIO ELECTRODE | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2025-11-13 | — | — | US | claimed |
| US-12396945-B2 | Soft chewable pharmaceutical products | INTERVET INC. (US) | 2025-08-26 | — | — | US | claimed |
| US-20250034732-A1 | CARBON-SUPPORTED NIO ELECTRODE | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2025-01-30 | — | — | US | claimed |
| EP-2833866-B2 | SOFT CHEWABLE PHARMACEUTICAL PRODUCTS | INTERVET INT BV (NL) | 2024-11-27 | — | — | EP | claimed |
| US-20240350590-A1 | COMPOSITION FOR ORALLY ADMINISTERED FORMULATION CONTAINING GLP-1 ANALOGUE | HANMI PHARM. CO., LTD. (KR) | 2024-10-24 | — | — | US | claimed |
| WO-2024208829-A1 | METHODS OF MANUFACTURING PEPTIDE SALTS | FERRING B.V. (NL) | 2024-10-10 | — | — | WO | claimed |
| US-12084425-B2 | Method for preparing escitalopram bis-hydroxynaphtoate crystal form a | ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD (CN) | 2024-09-10 | — | — | US | claimed |
| EP-4371577-A1 | COMPOSITION FOR ORALLY ADMINISTERED FORMULATION CONTAINING GLP-1 ANALOGUE | Hanmi Pharm. Co., Ltd. (KR) | 2024-05-22 | — | — | EP | claimed |
| EP-1648338-A1 | COMPOSITE ABSORBABLE/BIODEGRADABLE RINGS FOR CONTROLLED DRUG DELIVERY | Poly-Med, Inc. (US) | 2006-04-26 | — | — | EP | claimed |
| CN-1185210-C | Use of pamoic acids for the preparation of a medicament for the treatment of diseases characterized by deposits of amyloid aggregates | SIGMA TAU IND FARMACEUTI (IT) | 2005-01-19 | — | — | CN | claimed |
| WO-2005002471-A1 | COMPOSITE ABSORBABLE/BIODEGRADABLE RINGS FOR CONTROLLED DRUG DELIVERY | POLY-MED, INC. (US) | 2005-01-13 | — | — | WO | claimed |
| US-20040265355-A1 | Composite absorbable/biodegradable rings for controlled drug delivery | POLY-MED, INC. | 2004-12-30 | — | — | US | claimed |
| US-20040029963-A1 | Use of pamoic acid or one of its derivatives, or one of its analogues , for the preparation of a medicament for the treatment of diseases characterised by deposits of amyloid aggregates | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2004-02-12 | — | — | US | claimed |
| CN-1449375-A | Use of pamoic acid or one of derivatives or analogs thereof for preparing a medicament used for treating diseases | SIGMA TAU IND FARMACEUTI (IT) | 2003-10-15 | — | — | CN | claimed |
| EP-1301463-A1 | USE OF PAMOIC ACID OR ONE OF ITS DERIVATIVES, OR ONE OF ITS ANALOGUES, FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF DISEASES CHARACTERISED BY DEPOSITS OF AMYLOID AGGREGATES | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 2003-04-16 | — | — | EP | claimed |
| WO-2002000603-A1 | USE OF PAMOIC ACID OR ONE OF ITS DERIVATIVES, OR ONE OF ITS ANALOGUES, FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF DISEASES CHARACTERISED BY DEPOSITS OF AMYLOID AGGREGATES | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2002-01-03 | — | — | WO | claimed |
| US-4291026-A | ISOLATION FROM MASH BY COMPLEXING WITH SALTS; ANIMAL FEEDS | AMERICAN CYANAMID COMPANY (US) | 1981-09-22 | — | — | US | claimed |
| EP-0024508-A2 | Antibiotic BM123-gamma pamoate complexes, process for their preparation and compositions containing them | AMERICAN CYANAMID COMPANY (US) | 1981-03-11 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12084425-B2 | Method for preparing escitalopram bis-hydroxynaphtoate crystal form a | HTR1F, HTR1A, HSD17B1 | HTR2A 49/4885GPR35 2287/4885POLB 447/4885 |
| US-12396945-B2 | Soft chewable pharmaceutical products | PAM, TAS2R46, TAS2R16 | HTR2A 558/4885GPR35 921/4885POLB 3624/4885 |
| US-20040029963-A1 | Use of pamoic acid or one of its derivatives, or one of its analogues , for the preparation of a medicament for the treatment of diseases characterised by deposits of amyloid aggregates | APP, PSEN1, TTR | HTR2A 816/4885GPR35 788/4885POLB 3193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.